Exchange: NASDAQ·Updated 07:30 PM EST

SNY News

News
all
press releases
2,314,577 Sanofi $SNY Shares Sold by Barrow Hanley Mewhinney & Strauss LLC
Barrow Hanley Mewhinney & Strauss LLC reduced its stake in Sanofi (NASDAQ:SNY - Free Report) by 86.3% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 366,396 shares of the company's stock after selling 2,314,577 shares dur...
MarketBeat
2,314,577 Sanofi $SNY Shares Sold by Barrow Hanley Mewhinney & Strauss LLC
Barrow Hanley Mewhinney & Strauss LLC reduced its stake in Sanofi (NASDAQ:SNY - Free Report) by 86.3% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 366,396 shares of the company's stock after selling 2,314,577 shares dur...
MarketBeat
More News
Sanofi weighs potential Insmed acquisition to offset Dupixent patent loss, prompting analysts to weigh respiratory synergy against deal cost and capacity.read more...
Benzinga
Insmed Inc. (NASDAQ: INSM) shares are rising. A report surfaced that Sanofi is exploring an offer for the rare-disease drug developer.read more...
Benzinga
Sanofi (NASDAQ:SNY) is advancing a slate of vaccine candidates targeting respiratory infections, pneumococcal disease and acne, with several clinical readouts expected over the next 18 months, according to its head of vaccines research and development. Jean-Francois Toussaint said the company...
MarketBeat
Futures Tumble As Anthropic IPO Hangover Turns AI Unwind Into Global Rout US futures are lower for a second day as the AI unwind turns into a global liquidation: a day after its record-setting debut, Anthropic is sliding in premarket trading as the biggest IPO ever turns into a...
Zero Hedge
An ongoing shortage of Sanofi's Pompe disease treatment is forcing some patients to miss critical doses. They worry their health is at risk...
CNBC: Healthcare
Insmed stock rose as much as 24% on Thursday, and any deal could be weeks away, according to Bloomberg...
Quartz
Insmed (INSM) stock surges over 18% after reports that French pharma giant Sanofi (SNY) is exploring a potential takeover.read more...
Benzinga
Sanofi is talking to advisers and studying a potential deal for Insmed, Bloomberg reported, citing unnamed people familiar with the matter.
Stocktwits
SNY wins EU approval for VaxRabeo, its next-generation rabies vaccine, offering improved stability, flexible dosing and reduced allergy risks.
Zacks

Advertisement|Remove ads.